A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma.

MLA

Ikoma, Yoshikazu, et al. “A Phase II Study of Gemcitabine, Carboplatin, Dexamethasone, and Rituximab in Patients with Relapsed or Refractory Non‐Hodgkin Lymphoma.” Hematological Oncology, vol. 42, no. 1, Jan. 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1002/hon.3236.

APA

Ikoma, Y., Nakamura, N., Kitagawa, J., Miwa, T., Takada, E., Matsumoto, T., Shibata, Y., Nakamura, H., Kanemura, N., Kasahara, S., Hara, T., Sawada, M., Tsurumi, H., & Shimizu, M. (2024). A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma. Hematological Oncology, 42(1), 1–9. https://doi.org/10.1002/hon.3236

Chicago

Ikoma, Yoshikazu, Nobuhiko Nakamura, Junichi Kitagawa, Takao Miwa, Eri Takada, Takuro Matsumoto, Yuhei Shibata, et al. 2024. “A Phase II Study of Gemcitabine, Carboplatin, Dexamethasone, and Rituximab in Patients with Relapsed or Refractory Non‐Hodgkin Lymphoma.” Hematological Oncology 42 (1): 1–9. doi:10.1002/hon.3236.